A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants

Study Identifier
M22-080
CT.gov Identifier
NCT06137287
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Toxins
    • Study Drug
  • BOTOX
  • Placebo for BOTOX
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18 - 64 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Adult Japanese individuals. * Participant with marked or very marked masseter muscle prominence (MMP).
    Exclusion Criteria:
    * Asymmetry of left and right sides of the face that could prevent identical Masseter Muscle Prominence Scale (MMPS) or MMPS-P grading on both sides of the face, as determined by the investigator. * History of permanent soft tissue fillers in the jawline.

    Protocol Summary

    The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a narrower and more ovoid lower face shape. Treatments are available for masseter muscle prominence (MMP), but researchers are looking for new non-surgical treatments. This study will assess adverse events and effectiveness of BOTOX in adult participants with MMP.

    BOTOX is being investigated for the treatment of MMP. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. There is 1 in 5 chance that participants will be assigned to placebo. Around 250 adult participants with MMP will be enrolled in the study at approximately 20 sites in Japan.

    Participants will receive either BOTOX or Placebo administered as 6 intramuscular injections to each masseter muscle on Day 1. Participants who are eligible for retreatment will be given BOTOX on either Day 180, 210, 240, or 270 and will be followed until approximately Day 360.

    There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, facial photography, checking for side effects and completing questionnaires.

    Study Locations

    Location
    Status
    Location
    Jyosui Dermatology Clinic /ID# 254300
    Fukuoka, Fukuoka, Japan, 810-0022
    Status
    Not applicable
    Location
    Kotoni Tower Skin And Cosmetic Surgery Clinic /ID# 260668
    Sapporo, Hokkaido, Japan, 063-0812
    Status
    Not applicable
    Location
    Tokai University Hospital /ID# 254204
    Isehara, Kanagawa, Japan, 259-1193
    Status
    Not applicable
    Location
    Yoshikawa Skin Ecru Clinic /ID# 256505
    Kyoto, Kyoto, Japan, 604-8035
    Status
    Not applicable
    Location
    Touyama Plastic Surgery Clinic /ID# 254831
    Naha, Okinawa, Japan, 900-0015
    Status
    Not applicable
    Location
    Dermatology and Ophthalmology Kume Clinic /ID# 254632
    Sakai-shi, Osaka, Japan, 593-8324
    Status
    Not applicable
    Showing {first} - {last} of {total} Results